Transitioning to Pegylated Interferon for the Treatment of Cutaneous T-Cell Lymphoma: Meeting the Challenge of Therapy Discontinuation and a Proposed Algorithm

Table 3

Prior therapies to interferon that were trialed in the presented cohort of patients.

Patient	Number of lines of treatment prior to IFN	Previously trialed therapies
1	1	TCS, ECP
2	1	TCS, ECP
	4	TCS, phototherapy (broad band), retinoids, radiation, methotrexate
4	3	TCS, phototherapy, retinoids, radiation
	9	TCS, PUVA, TSEB, methotrexate, nitrogen mustard, interferon (2014–2016), chemotherapy, bortezomib, isotretinoin
	7	TCS, phototherapy, chemotherapy, retinoids, brentuximab vedotin
7	5	TCS, PUVA, radiation, retinoids, imiquimod
	4	TCS, ECP, interferon (2016), retinoids (alitretinoin, isotretinoin)

Patients who received interferon before the course in which they were switched to pegylated interferon. TCS, topical corticosteroids; ECP, extracorporeal photopheresis; PUVA, psoralen + UVA; TSEB, total skin electron beam therapy; IFN, interferon.